Interim data presented in poster reflects median overall survival of 12.0 months, not yet final, and an objective response rate of 48%, both greater than historical rates reported for standard of care
Development Program for SBP-101’s Expansion into Ovarian Cancer Expected in 1H 2022
Patent developed in collaboration with Syngene International Ltd
Events & Presentations